OmniAb (OABI) Capital Expenditures (2022 - 2026)
OmniAb (OABI) reported Capital Expenditures of $167000.0 for Q1 2026, down 20.1% year-over-year from $209000.0 in Q1 2025, and up 1755.56% on a QoQ basis from $9000.0 in Q4 2025.
OmniAb (OABI) has 5 years of Capital Expenditures data on file, last reported at $167000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 20.1% year-over-year to $167000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $523000.0 (up 393.82% YoY) and the FY2025 annual result came in at $565000.0, up 633.77% from the prior year.
- Capital Expenditures advanced to $167000.0 in Q1 2026 per OABI's latest filing, from $9000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.5 million in Q1 2022 and bottomed at -$3.5 million in Q4 2022.
- The 5-year median for Capital Expenditures is $182000.0 (2025), against an average of $88117.6.
- The widest annual swing landed in 2023, when Capital Expenditures slumped 2447.5%; it then jumped 264.28% in 2024.
- Tracing OABI's Capital Expenditures over 5 years: stood at -$3.5 million in 2022, then jumped by 118.06% to $639000.0 in 2023, then sank by 374.18% to -$1.8 million in 2024, then jumped by 100.51% to $9000.0 in 2025, then surged by 1755.56% to $167000.0 in 2026.
- Per Business Quant, the three latest OABI Capital Expenditures figures stand at $167000.0 (Q1 2026), $9000.0 (Q4 2025), and $182000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 167,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 167,000.00 |
| Mar 31, 2026 | 167,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 182,000.00 |
| Sep 30, 2025 | 182,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Jun 30, 2025 | 165,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Dec 31, 2024 | -1.75 Mn |
| Dec 31, 2024 | -1.75 Mn |
| Sep 30, 2024 | 1.67 Mn |
| Sep 30, 2024 | 1.67 Mn |
| Jun 30, 2024 | -309,000.00 |
| Jun 30, 2024 | -309,000.00 |
| Mar 31, 2024 | 464,000.00 |
| Mar 31, 2024 | 464,000.00 |
| Dec 31, 2023 | 639,000.00 |
| Dec 31, 2023 | 639,000.00 |
| Sep 30, 2023 | -1.02 Mn |
| Sep 30, 2023 | -1.02 Mn |
| Jun 30, 2023 | 813,000.00 |
| Jun 30, 2023 | 813,000.00 |
| Mar 31, 2023 | 234,000.00 |
| Mar 31, 2023 | 234,000.00 |
| Dec 31, 2022 | -3.54 Mn |
| Dec 31, 2022 | -3.54 Mn |
| Sep 30, 2022 | -40,000.00 |
| Sep 30, 2022 | -40,000.00 |
| Jun 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 2.51 Mn |
| Mar 31, 2022 | 2.51 Mn |